PyVs (18). In addition, we recently identified more than 20 novel PyVs in a number of non-69 human primates (NHP), including apes ((13) and N. Scuda, F. Leendertz and B. Ehlers, 70 unpublished data). These new PyVs nearly span the entire known diversity of mammalian 71
PyVs, which suggests that primates as a whole, including humans, are infected with a plethora 72 of PyVs. 73 To further test this hypothesis, we screened DNA extracts from 597 clinical samples for 74 the presence of PyVs. The majority of the samples were from immunocompromised 75 transplant recipients, leukoencephalopathy (LEP) patients and HIV-positive patients (serum, 76 plasma, urine or whole blood) that had originally been collected for BKV and herpes virus 77 diagnostics at three German university hospitals (Table 1 ). In addition, cerebrospinal fluid 78 (CSF) samples from LEP patients, bronchoalveolar lavage (BAL) from patients with 79 pneumonia and fecal samples from children with diarrhoea were tested (Table 1) . A generic 80 PCR assay using degenerate and deoxyinosine-substituted primers was used as described 81 previously (13). The primers had been designed to target conserved regions in the VP1 genes 82 of the known PyVs (except the highly divergent PyV group represented by KIV, WUV, 83
HPyV6 and HPyV7). From 85/597 samples, VP1 sequences could be determined as shown by 84 sequencing and BLAST analysis (2) in GenBank. All of these PyVs except one were known: 85 BKV (n=56), JCV (n=18), MCPyV (n=8) and TSV (n=2) ( Table 1 ). The PyV sequences were 86 amplified from plasma (12/176), urine (71/179) and BAL (1/21) samples. CSF (n=74), whole 87 blood (n=21), serum (n=87) and fecal (n=38) samples were negative (Table 1) . 88
Most importantly, an unknown PyV sequence was amplified from the serum of a kidney 89 transplant patient under immunosuppressive treatment. In BLAST analysis it revealed the 90 closest similarity to the VP1 gene of LPV (pairwise nucleic acid identity: 83%). To obtain 91 additional sequence information of the novel PyV, a 950 bp genome fragment spanning parts 92 of the VP3 and VP1 genes was amplified. For this purpose, two degenerate sense primers 93 derived from the VP3 sequence of LPV and two specific antisense primers deduced from the 94 novel VP1 sequence were used in a nested PCR. Based on the resulting sequence, primers 95 were designed tail-to-tail for the amplification and sequencing of the remaining part of the 96 genome, and used in nested long-distance (LD-) PCR (all primer sequences and PCR reaction 97 conditions are shown in Tables S1 and S2 of the supplemental material). A final circular 98 genome of 5026 bp was obtained, and confirmed to be more similar to the LPV genome 99 (pairwise nucleic acid identity: 76%) than to those of other PyVs (<60%). Since eight human 100
PyVs are presently known, the virus from which the genome originated was tentatively named 101 Human Polyomavirus 9 (HPyV9). 102 on July 7, 2017 by guest http://jvi.asm.org/
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Examination of putative open reading frames (ORFs) showed that the genome of 103
HPyV9 has a typical PyV structure with an early region encoding regulatory proteins (small t 104 and large T antigens) and a late region coding for structural proteins (VP1, VP2 and VP3) 105 separated by a non-coding control region (NCCR) ( Figure 1A ). HPyV9 lacked any ORF 106 encoding an agnoprotein. The ORF locations on the viral genome and their similarity to LPV 107 and other human PyVs are listed in the Table S3 in the supplemental material. Over the entire 108 genome length HPyV9 and LPV revealed a high similarity (see Figure S4 in the supplemental 109 material) including functionally important sites in the NCCR and the large T and VP1 110 proteins ( Figures 1B-1D , respectively). 111
Phylogenetic analyses were performed using a concatenated dataset of VP1, VP2 and 112 large T sequences including HPyV9 as well as a representative collection of published PyVs 113 (Table S5 of the supplemental material). Preparation of the dataset as well as downstream 114 analyses, including maximum likelihood (ML) and Bayesian tree reconstructions were 115 conducted as described previously (13). The resulting tree evidenced the close relationship of 116
HPyV9 and LPV, which formed a highly supported monophyletic group -bootstrap (Bp) and 117 posterior probability (pp) values: 100 and 1 (Figure 2) . 118
To determine whether individuals other than the index case were infected with HPyV9, 119 all 597 samples were re-screened with HPyV9-specific nested PCR using primers deduced 120 from the VP1 sequence (see Tables S1 and S2 in the supplemental material). In four 121 additional samples (serum, plasma, whole blood and urine), VP1 sequences of HPyV9 were 122 detected (100% nucleic acid sequence identity to the index VP1 sequence). All CSF and BAL 123 samples were negative (Table 1) . In attempting to amplify complete genomes sequences from 124 these samples, PyV genomes were pre-amplified by using the Templiphi 100 rolling circle 125 amplification kit, according to the instructions of the manufacturer (GE Healthcare, BKV from SV40 (10). Then, it was also shown that antibodies raised against one or the other 154 strains of BKV could occasionally discriminate subgroups in neutralization assays (11) while 155 the maximum VP1 genetic distance within BKV is largely outscored by the genetic distance 156 between LPV/AGMPyV and HPyV9 VP1 ( Figure S6 of the Supplementary Material). All in 157 all, these contrasted results prevent any firm prediction of cross-reactivity that would be 158 solely based on genetic make-up. However, we propose that HPyV9 could at least be 159 considered one good candidate for the frequent LPV-like serological reactivity observed in 160 human populations, acknowledging that other PyVs might be involved as well. Another good 161 candidate PyV could be LPV itself whose short DNA fragments were recently detected in 162 CSF and blood of AIDS patients as well as in blood of healthy subjects (5). Other authors 163 analysed patients suffering from progressive multifocal leukoencephalopathy, and did not 164 detect LPV while using specific primers (7). Our data do not provide evidence of LPV 165 infection in immunocompromised patients either. If the prevalence of both HPyV9 and LPV 166 infection in human populations can be confirmed to be at low levels, the existence of other 167 antigenically related, yet unknown human PyVs must be postulated. 
